Rankings
▼
Calendar
KNSA Q1 2025 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena
KNSA
Kiniksa Pharmaceuticals, Ltd.
$3B
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$138M
+72.5% YoY
Gross Profit
$76M
55.3% margin
Operating Income
$13M
9.6% margin
Net Income
$9M
6.2% margin
EPS (Diluted)
$0.11
QoQ Revenue Growth
+12.4%
Cash Flow
Operating Cash Flow
$22M
Free Cash Flow
$22M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$599M
Total Liabilities
$142M
Stockholders' Equity
$457M
Cash & Equivalents
$157M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$138M
$80M
+72.5%
Gross Profit
$76M
$48M
+57.5%
Operating Income
$13M
-$17M
+180.2%
Net Income
$9M
-$18M
+148.2%
Revenue Segments
Product
$138M
100%
← FY 2025
All Quarters
Q2 2025 →